Latest Period
Q4 2025
Security Snapshot
Damora Therapeutics, Inc. - Common Stock, $0.00001 par value per share (DMRA) Institutional Ownership
CUSIP: 36322Q206
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
18
Shares (Excl. Options)
1,107,880
Price
$23.01
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.00001 par value per share
- Symbol
- DMRA on Nasdaq
- Shares outstanding
- 60,059,917
- Price per share
- $25.60
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 1,107,880
- Total reported value
- $25,492,284
- % of total 13F portfolios
- 0%
- Share change
- +817,177
- Value change
- +$21,929,226
- Number of holders
- 18
- Price from insider filings
- $25.60
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- DMRA - Damora Therapeutics, Inc. - Common Stock, $0.00001 par value per share is tracked under CUSIP 36322Q206.
- 18 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 18 to 20 between Q4 2025 and Q1 2026.
- Reported value moved from $25,492,284 to $113,012,968.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 18 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 36322Q206?
CUSIP 36322Q206 identifies DMRA - Damora Therapeutics, Inc. - Common Stock, $0.00001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 36322Q206:
Significant Owners of Damora Therapeutics, Inc. - Common Stock, $0.00001 par value per share (DMRA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $190,117,660 | +$181,455,120 | 8,713,000 | +2095% | Fairmount Funds Management LLC | 09 Feb 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 6% | $78,630,443 | 3,603,595 | Venrock Healthcare Capital Partners III, L.P. | 09 Feb 2026 | |||
| FMR LLC | 15% | $6,650,364 | 238,878 | FMR LLC | 28 Nov 2025 | |||
| Jain Global LLC | 7.5% | $2,630,750 | 120,566 | Jain Global LLC | 31 Dec 2025 | |||
| Paramora Holding LLC | 7.5% | $3,494,922 | 120,473 | Paramora Holding LLC | 10 Nov 2025 | |||
| Paragon Therapeutics, Inc. | 7.5% | $3,494,922 | 120,473 | Paragon Therapeutics, Inc. | 10 Nov 2025 | |||
| Point72 Asset Management, L.P. | 6.3% | $372,164 | 100,001 | Point72 Asset Management, L.P. | 12 Nov 2025 |
As of 31 Dec 2025, 18 institutional investors reported holding 1,107,880 shares of Damora Therapeutics, Inc. - Common Stock, $0.00001 par value per share (DMRA). This represents 1.8% of the company’s total 60,059,917 outstanding shares.
Institutional Holders of Damora Therapeutics, Inc. - Common Stock, $0.00001 par value per share (DMRA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,363,463 | $113,012,968 | +$101,114,630 | $25.90 | 20 |
| 2025 Q4 | 1,107,880 | $25,492,284 | +$21,929,226 | $23.01 | 18 |
| 2025 Q3 | 170,205 | $633,327 | +$144,879 | $3.72 | 12 |
| 2025 Q2 | 132,660 | $451,146 | -$30,019 | $3.41 | 8 |
| 2025 Q1 | 142,568 | $441,959 | +$1,278 | $3.10 | 10 |
| 2024 Q4 | 142,062 | $660,654 | +$59,803 | $4.65 | 10 |
| 2024 Q3 | 128,626 | $1,562,807 | +$1,556,853 | $12.15 | 9 |